Trial reportThe Veterinary record2015
Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.
Trial report in The Veterinary record, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.BMC veterinary research · 2018Trial
- The Potential of Selective COX-2 Inhibitor Mavacoxib for Extended Analgesia in Sheep Husbandry.Animals : an open access journal from MDPI · 2026Article
- Assembly of CFThe Journal of organic chemistry · 2026Article
- A randomized, double-blind, controlled study on the efficacy of an oral dietary supplement containing fish oil, ASU and phytotherapeutic extracts in canine osteoarthritis.Frontiers in veterinary science · 2025Article
- Enflicoxib for the long-term management of canine osteoarthritis-External validation of a population pharmacokinetic model in dogs with osteoarthritis.Frontiers in veterinary science · 2025Article
- A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs.Frontiers in veterinary science · 2024Article
- Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing.Arthritis research & therapy · 2023Article
- Advances in the pharmaceutical treatment options for canine osteoarthritis.The Journal of small animal practice · 2022Review
- Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib.PloS one · 2022Article
- Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic.Equine veterinary education · 2020Article
- Pedobarography: a novel approach to test the efficacy of treatments for lameness; an experience with mavacoxib in dogs with elbow osteoarthritis.BMC veterinary research · 2019Article
- Agmatine for Pain Management in Dogs With Coxofemoral Joint Osteoarthritis: A Pilot Study.Frontiers in veterinary science · 2018Article
- Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.Journal of the American Veterinary Medical Association · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days. Treatments were administered according to their respective summaries of product characteristics. Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen. Both treatments resulted in a very similar pattern of considerable improvement as indicated in all parameters assessed by both owner and veterinarian. The primary efficacy endpoint 'overall improvement' was a composite score of owner assessments after approximately six weeks of treatment. Both drugs were remarkably effective, with 57/61 (93.4 per cent) of mavacoxib-treated dogs and 49/55 (89.1 per cent) of carprofen-treated dogs demonstrating overall improvement and with mavacoxib's efficacy being non-inferior to carprofen. The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters. The positive clinical response to treatment along with the safety and dosing regimen of mavacoxib makes it an attractive therapy for canine osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.